Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use

Cancer Treatment Reviews

Volumn 35, Issue 3, 2009, Pages 246-254

  Feliu, Jaime ^a   Sereno, María ^b   Castro, Javier De ^a   Belda, Cristóbal ^a   Casado, Enrique ^b   González Barón, Manuel ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

Adjuvancy; Chemotherapy; Colorectal cancer; Elderly; Frailty

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CREATININE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PANITUMUMAB; RALTITREXED; UFT;

ADJUVANT THERAPY; AGED; AGING; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; COMORBIDITY; CONTINUOUS INFUSION; CREATININE CLEARANCE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ELDERLY CARE; FEBRILE NEUTROPENIA; FRAIL ELDERLY; GASTROINTESTINAL DISEASE; GERIATRIC ASSESSMENT; HAND FOOT SYNDROME; HEALTH STATUS; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INDIVIDUALIZATION; INTESTINE INJURY; LEUKOPENIA; LIFE EXPECTANCY; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PATIENT CARE; PATIENT SELECTION; PROGNOSIS; PROTEINURIA; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; RECURRENCE RISK; REVIEW; RISK REDUCTION; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMORBIDITY; DISEASE SUSCEPTIBILITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FRAIL ELDERLY; GERIATRICS; HUMANS; LEUCOVORIN; MALE; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PATIENT SELECTION; PROSPECTIVE STUDIES;

EID: 64049098470     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.11.004     Document Type: Review

References (78)

1. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 16 (2005) 481-488
2. Colorectal cancer collaborative group. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 356 (2000) 968-974
3. Schrag D., Cramer L.D., Bach P.B., and Begg C.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93 (2001) 850-857
4. Yee K.W., Pater J.L., Pho L., et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?. J Clin Oncol 21 (2003) 1618-1623
5. Gross C.P., McAvay G.J., Guo Z., and Tinetti M.E. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 109 (2007) 2410-2419
6. Carreca I., Balducci L., and Extreman M. Cancer in the older person. Cancer Treatment Rev 31 (2005) 380-402
7. Ferruci L., Guralnik J.M., Cavazzini C., et al. The frailty syndrome: a critical issue in geriatric oncology. Crit Rev Oncol Hematol 46 (2003) 127-137
8. Balducci L., and Extermann M. Management of cancer in the older person: a practical approach. The Oncologist 5 (2000) 224-237
9. Extermann M., Overcash J., Lyman G.H., et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 (1998) 1582-1587
10. Gosney M.A. Clinical assessment of elderly people with cancer. Lancet Oncol 6 (2005) 790-797
11. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the international society of geriatric oncology. Crit Rev in Oncol Hematol 55 (2005) 241-252
12. Fried L.P., Tangen C.M., Waltson J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol Med Sci 56A (2001) 146-156
13. Lewis J.H., Kilgore M.L., Goldman D.P., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 (2003) 1383-1389
14. Honecker F., Kohne C.H., and Bokemeyer C. Colorectal cancer in the elderly: is palliative chemotherapy of value?. Drugs Aging 20 (2003) 1-11
15. Shaine M., Culakova E., Poniewierski M.S., Wolff D., Dale D.C., Crawford J., et al. Dose intensity hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 110 (2007) 1611-1620
16. Lichtman S.M. Chemotherapy in the elderly. Semin Oncol 31 (2004) 160-174
17. Stein B.N., Petrelli N.J., Dougass H.O., et al. Age and sex are independent factors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer 75 (1995) 11-17
18. Köhne C.H., Cunningham D., Di Costanzo F., et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate análisis of 3825 patients. Ann Oncol 13 (2002) 308-317
19. Cassidy J., Twelves C., Van Cutsem E., et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13 (2002) 566-575
20. Chau I., Norman A.R., Cunningham D., et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Brit J Cancer 91 (2004) 1453-1458
21. Rothenberg M.L., Cox J.V., De Vore F.R., et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85 (1999) 786-795
22. Rougier P., Mitry E., Cunningham D., et al. Is age a prognostic factor of toxicity and efficacy in patients with metastatic colorectal cancer receiving irinotecan in combination with 5FU/folinic acid (FA). Proc Am Soc Clin Oncol 21 (2003) 267 [abstract 1072]
23. Schaaf L., Ichpurani N., Elfring G., et al. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G) in patients with previously treated colorectal cancer. Proc Am Soc Clin Oncol 15 (1997) 708
24. Saltz L., Cox J., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 (2000) 905-914
25. De Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
26. Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy analysis of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 (2006) 4085-4091
27. Sastre J., Aranda E., Gravalos C., et al. Single agent cetuximab for elderly patients with advanced colorectal cancer. Preliminary results of a TTD phase II study. Proc ESMO 17 (2006) 114 [abstract 3240]
28. Bouchahda M., Macarulla T., Spano J.P., et al. Cetuximab and irinotecan-based chemotherapy as an active and safe treatment option for elderly patients with extensively pre-treated metastatic colorectal cancer. Proc Am Soc Clin Oncol (2007) 25 [abstract 14528]
29. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitunumab plus best supportive care compared with best supportive care alone in patients with chemotherapy - refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
30. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
31. Moertel C.G., Fleming T.R., MacDonald J.S., et al. Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N Engl J Med 322 (1990) 352-358
32. Anonymous. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled análisis of colon cancer trials (IMPACT) investigators. Lancet 345 (1995) 939-944
33. André T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
34. Kuebler J.P., Wieand H.S., ÓConnell M.J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 (2007) 2198-2204
35. Jessup J.M., Stewart A., Greene F.L., and Minsky B.D. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294 (2005) 2758-2760
36. Sargent D.J., Goldberg R.M., Jacobson S.D., and Macdonald J.S. A pooled analysis of adjuvant chemotherapy for resected colon cancer in the elderly. N Engl J Med 345 (2001) 1091-1097
37. Kohne C.H., Grothey A., Bokemeyer C., Barthke N., and Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 12 (2001) 435-442
38. Lemmens V.E.P.P., van Halteren A.H., Janssen-Heijnen M.L., et al. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender and comorbidity. Ann Oncol 16 (2005) 767-772
39. Morris M., Platell C., Fritschi L., and Iacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Brit J Cancer 96 (2007) 701-707
40. Cronin D.P., Harlan L.C., Potosky A.L., et al. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 101 (2006) 2308-2318
41. Sanoff H.K., Bleiberg H., and Goldberg R.M. Managing older patients with colorectal cancer. J Clin Oncol 25 (2007) 1891-1897
42. Gross C.P., McAvay G.J., Krumholz H.M., et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Int Med 145 (2006) 646-653
43. Lembersky B.C., Wieand H.S., Petrelli N.J., et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from national surgical adjuvant breast and bowel project protocol C-06. J Clin Oncol 24 (2006) 2059-2064
44. Twelves C., Wong A., Nowacki M.P., Abt M., Burris III H., Carrato A., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696-2704
45. Chau I., Norman A.R., Cunningham D., et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of proctracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16 (2005) 549-557
46. Neugut A.I., Matasar M., Wang X., et al. Duration of adjuvant chemotherapy for colon cancer and survival among elderly. J Clin Oncol 24 (2006) 2368-2375
47. Dobie S.A., Baldwin L.M., Dominitz J.A., Matthews B., Billingsley K., and Barlow W. Completion of therapy by medicare patients with stage III colon cancer. J Natl Cancer Inst 98 (2006) 610-619
48. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. The Oncologist 10 (2005) 250-261
49. Folprecht G., Seymour T., Saltz L., Douillard J.Y., Stephens R.J., Van Cutsem E., et al. Irinotecan/5-FU/FA (I-FU) or FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: combined analysis of 2.691 patients in randomized controlled trials. Proc Am Soc Clin Oncol 25 (2007) 181 [abstract 4071]
50. Extermann M., Albrand G., Chen H., et al. Are older French patients as willing as older American patients to undertake chemotherapy?. J Clin Oncol 21 (2003) 3214-3219
51. Yellen S.B., Cella D.F., and Leslie W.T. Age and clinical decision making in oncology patients. J Natl Inst 86 (1994) 1766-1770
52. Elkin E.B., Kim H.M., Casper E.S., Kissane D.W., and Schrag D. Desire for information and involvement in treatment decisions; elderly cancer patientś preferences and their physicianśperceptions. J Clin Oncol 25 (2007) 5375-5380
53. André T., Bansmaine M.A., Louvet C., et al. Multicenter phase II study of bimonthly high dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17 (1999) 3560-3568
54. Comella P., Natale D., Farris A., et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Cancer 104 (2005) 282-289
55. Feliu J., Salud A., Escudero P., et al. XELOX (Capecitabine plus Oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Brit J Cancer 94 (2006) 969-975
56. Figer A., Perez N., Carola E., Tournigand C., Lledo G., Flesch M., et al. FOLFOX in patients aged between 78 and 80 years with metastatic colorectal cancer. An exploratory cohort of the OPTIMOX study. Cancer 110 (2007) 2666-2671
57. Mattioli R., Massacesi C., Recchia F., et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 16 (2005) 1147-1151
58. Sastre J., Marcuello E., Massutti B., et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 23 (2005) 3545-3551
59. Souglakos J., Pallis A., Kakolyris D., et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 69 (2005) 384-390
60. Rosati G., Cordio S., Tucci A., et al. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 69 (2005) 122-129
61. Aparicio T., Desrame J., Lecomte T., et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Brit J Cancer 89 (2003) 1439-1444
62. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop- and- go fashion in advanced colorectal cancer-A GERCOR Study. J Clin Oncol 24 (2006) 394-400
63. Cassidy J., Bjarnason G.A., Hickish T., et al. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first line treatment of patients (pts) with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 26 (2006) 147 [abstract 3507]
64. Cassidy J., Tabernero J., Twelves C., et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22 (2004) 2084-2091
65. Köne C.H., Folprecht G., Goldberg R., Mitry E., and Rougier P. Chemotherapy in elderly patients with colorectal cancer. The Oncologist 13 (2008) 390-402
66. Comella P., Farris A., Lorusso V., et al. Irinotecan plus leucovorin-modulated 5-fluorouracil I. V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma. Br J Cancer 89 (2003) 992-996
67. Ashley A.C., Sargent D.J., Alberts S.R., et al. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX). Intergroup trial N9741 in forst-line treatment of metastatic colorectal cancer. Cancer 110 (2007) 670-677
68. Maas H.A.A.M., Janssen-Heijnen M.L.G., Rikkert M.G.M.O., and Wymenga A.N.M. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 43 (2007) 2161-2169
69. Seymour M.T., Maughan T.S., Ledermann J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 (2007) 143-152
70. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
71. Seymour M.T., Maughan T.S., Wasan H.S., et al. Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: the FOCUS2 trial. Proc Am Soc Clin Oncol 28 (2007) 9030
72. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24 (2006) 394-400
73. Feliu J., González-Barón M., Espinosa E., et al. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz cooperative group. Cancer 79 (1997) 1884-1889
74. Abad A. UFT plus folinic acid as therapy for metastatic colorectal cancer in older patients. Oncology 11 (1999) 53-57
75. Hochster H., Luo W., Popa E.C., et al. Phase II study of Uracil-Tegafur with Leucovorin in elderly (≥75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol 25 (2007) 5397-5402
76. Feliu J., Mel J.R., Camps C., et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. Eur J Cancer 38 (2002) 1204-1211
77. Feliu J., Escudero P., Llosa F., et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Cin Oncol 23 (2005) 3104-3111
78. Kabbinavar F.F., Schultz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705